0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T20:53:00Z
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
Fri 18 Oct 24, 12:51 PMCRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Thu 10 Oct 24, 01:10 PMCRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
Wed 18 Sep 24, 12:06 PMCRL Stock May Benefit From New Neuroscience Research Collaboration
Mon 09 Sep 24, 01:27 PMWhy Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Fri 06 Sep 24, 03:31 PMHigher Interest Environment Negatively Impacted Charles River Laboratories (CRL)
Fri 06 Sep 24, 02:05 PMCalculating The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Sun 01 Sep 24, 12:47 PMCharles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment
Wed 28 Aug 24, 08:46 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M |
| Minority interest | 6.38M | 7.86M | 1.00M | 2.04M | 2.35M |
| Net income | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M |
| Selling general administrative | 665.10M | 619.92M | 528.93M | 486.20M | 419.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1462.65M | 1334.64M | 1073.54M | 958.31M | 840.07M |
| Reconciled depreciation | 303.87M | 265.54M | 234.92M | 198.09M | 161.78M |
| Ebit | 650.98M | 589.86M | 432.73M | 351.15M | 345.45M |
| Ebitda | 986.15M | 820.16M | 768.47M | 563.06M | 410.28M |
| Depreciation and amortization | 335.17M | 230.30M | 335.74M | 211.91M | 64.83M |
| Non operating income net other | 31.30M | -35.24200M | 100.82M | 13.81M | 14.07M |
| Operating income | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M |
| Other operating expenses | 3325.09M | 2950.30M | 2491.20M | 2270.07M | 1934.71M |
| Interest expense | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M |
| Tax provision | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M |
| Interest income | 0.78M | 74.86M | 0.83M | 1.52M | 0.81M |
| Net interest income | -58.51100M | -73.25800M | -85.59900M | -59.36000M | -62.96000M |
| Extraordinary items | - | - | - | 0.00000M | 7.01M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M |
| Total revenue | 3976.06M | 3540.16M | 2923.93M | 2621.23M | 2266.10M |
| Total operating expenses | 811.68M | 744.78M | 640.81M | 607.16M | 508.68M |
| Cost of revenue | 2513.41M | 2205.52M | 1850.39M | 1662.91M | 1426.03M |
| Total other income expense net | -27.98800M | -109.15200M | 14.38M | -47.06700M | 13.26M |
| Discontinued operations | - | - | - | - | 1.51M |
| Net income from continuing ops | 492.61M | 398.84M | 365.31M | 254.06M | 227.22M |
| Net income applicable to common shares | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 7602.77M | 7024.29M | 5490.83M | 4692.79M | 3855.88M |
| Intangible assets | 955.27M | 1061.19M | 787.60M | 689.41M | 610.89M |
| Earning assets | - | - | - | - | - |
| Other current assets | 107.58M | 97.31M | 72.56M | 56.03M | 48.81M |
| Total liab | 4579.27M | 4432.30M | 3347.16M | 3026.32M | 2517.58M |
| Total stockholder equity | 2976.29M | 2534.82M | 2114.60M | 1634.58M | 1317.33M |
| Deferred long term liab | 215.58M | 239.72M | 217.03M | 167.28M | 143.63M |
| Other current liab | 621.41M | 612.56M | 459.12M | 388.33M | 315.42M |
| Common stock | 0.51M | 0.51M | 0.50M | 0.49M | 0.48M |
| Capital stock | 0.51M | 0.51M | 0.50M | 0.49M | 0.48M |
| Retained earnings | 1432.90M | 980.75M | 625.41M | 280.33M | 42.10M |
| Other liab | 390.40M | 482.58M | 422.25M | 350.22M | 322.76M |
| Good will | 2849.90M | 2711.88M | 1809.17M | 1540.57M | 1247.13M |
| Other assets | 0.00100M | -47.21100M | 1459.35M | 134.29M | 78.55M |
| Cash | 233.91M | 241.21M | 228.42M | 238.01M | 195.44M |
| Cash and equivalents | 233.91M | 241.21M | 228.42M | 238.01M | 195.44M |
| Total current liabilities | 1091.59M | 1033.18M | 839.75M | 710.18M | 558.22M |
| Current deferred revenue | 264.26M | 219.70M | 207.94M | 171.81M | 145.14M |
| Net debt | 2863.36M | 2678.12M | 1906.96M | 1766.45M | 1472.57M |
| Short term debt | 0.00000M | 2.79M | 50.21M | 38.55M | 31.42M |
| Short long term debt | - | 0.10M | 47.20M | 35.55M | 31.42M |
| Short long term debt total | 3097.28M | 2919.33M | 2135.38M | 2004.46M | 1668.01M |
| Other stockholder equity | 1804.94M | 1718.30M | 1627.56M | 1531.79M | 1447.46M |
| Property plant equipment | 1857.42M | 1584.01M | 1124.36M | 1044.13M | 932.88M |
| Total current assets | 1439.03M | 1274.10M | 1201.13M | 1021.33M | 897.84M |
| Long term investments | 311.60M | 201.35M | 221.80M | 122.98M | 88.59M |
| Net tangible assets | -786.45800M | -1185.24300M | -456.66600M | -566.74700M | -522.16400M |
| Short term investments | 1.00M | 1.06M | 1.02M | 0.94M | 0.89M |
| Net receivables | 752.39M | 642.88M | 617.74M | 514.03M | 472.25M |
| Long term debt | 2707.53M | 2639.03M | 1903.54M | 1822.14M | 1636.60M |
| Inventory | 255.81M | 199.15M | 185.69M | 160.66M | 127.89M |
| Accounts payable | 205.91M | 198.13M | 122.47M | 111.50M | 66.25M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 4.79M | 4.16M | 3.57M | 3.24M | 2.45M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -262.05700M | -164.74000M | -138.87400M | -178.01900M | -172.70300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.51M | 0.51M | 0.50M | 0.49M | 0.48M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 1432.90M | 980.75M | 625.41M | 280.33M | 42.10M |
| Treasury stock | - | - | - | - | -0.05500M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 148.28M | 151.54M | 130.82M | 89.64M | 55.17M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6163.74M | 5750.20M | 4289.70M | 3671.47M | 2958.04M |
| Capital lease obligations | 389.75M | 316.16M | 209.32M | 167.14M | - |
| Long term debt total | 2707.53M | 2663.56M | 1929.57M | 1849.67M | 1636.60M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -153.72500M | -39.02300M | -15.29100M | -21.39900M | 10.72M |
| Change to liabilities | -44.81600M | 89.20M | 41.23M | 33.17M | 9.91M |
| Total cashflows from investing activities | -607.92200M | -1437.93200M | -601.54400M | -681.50200M | -955.00300M |
| Net borrowings | 19.79M | 669.98M | 30.59M | 227.28M | 535.69M |
| Total cash from financing activities | -42.39700M | 672.60M | 47.25M | 231.94M | 558.06M |
| Change to operating activities | -8.92400M | 46.31M | 39.38M | 20.64M | -2.10700M |
| Net income | 492.61M | 398.84M | 365.31M | 254.06M | 227.22M |
| Change in cash | -5.10000M | 13.20M | -6.92700M | 42.73M | 30.99M |
| Begin period cash flow | 246.31M | 233.12M | 240.05M | 197.32M | 166.33M |
| End period cash flow | 241.21M | 246.31M | 233.12M | 240.05M | 197.32M |
| Total cash from operating activities | 619.64M | 760.80M | 546.58M | 480.94M | 441.14M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 303.87M | 265.54M | 234.92M | 198.09M | 161.78M |
| Other cashflows from investing activities | -129.46400M | -1170.13700M | -419.69300M | -519.58900M | -825.67300M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -78.52300M | -25.15900M | -18.37900M | -21.39900M | -13.33800M |
| Change to account receivables | -150.57000M | -26.63300M | -85.62700M | -8.32300M | -21.19600M |
| Sale purchase of stock | -38.65100M | -40.70700M | -23.97900M | -18.08700M | -13.84600M |
| Other cashflows from financing activities | 2903.78M | 6956.18M | 2271.63M | 3374.61M | 2772.91M |
| Change to netincome | -51.05900M | 23.06M | 73.48M | 22.60M | 33.59M |
| Capital expenditures | 324.73M | 228.77M | 166.56M | 140.51M | 140.05M |
| Change receivables | -150.57000M | -26.63300M | -85.62700M | -8.32300M | -21.19600M |
| Cash flows other operating | 148.13M | 35.95M | 300.95M | 256.79M | 266.66M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -30.67900M | -4.53500M | -7.72100M | 31.37M | 44.20M |
| Change in working capital | -152.55400M | 42.94M | -26.27500M | 6.18M | 14.81M |
| Stock based compensation | 73.62M | 71.47M | 56.34M | 57.27M | 47.35M |
| Other non cash items | -62.01700M | 6.01M | -83.58800M | -12.77500M | -0.31500M |
| Free cash flow | 294.91M | 532.03M | 380.01M | 340.42M | 301.09M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories |
6.53 3.48% | 194.43 | 25.57 | 20.12 | 2.82 | 3.59 | 3.47 | 13.72 |
| TMO Thermo Fisher Scientific Inc |
3.27 0.64% | 516.11 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
1.71 0.73% | 234.81 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-0.06 0.01% | 418.55 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
3.15 1.62% | 197.53 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
251 Ballardvale Street, Wilmington, MA, United States, 01887
| Name | Title | Year Born |
|---|---|---|
| Mr. James C. Foster J.D. | Chairman, CEO & Pres | 1951 |
| Ms. Birgit Girshick | Corp. Exec. VP & COO | 1970 |
| Mr. Joseph W. LaPlume | Corp. Exec. VP of Corp. Devel. & Strategy | 1974 |
| Mr. William D. Barbo | Chief Commercial Officer & Corp. Exec. VP | 1961 |
| Mr. David Ross Smith | Sr. Financial Advisor | 1966 |
| Ms. Flavia H. Pease | Corp. Exec. VP & CFO | NA |
| Mr. Michael Gunnar Knell | Corp. Sr. VP & Chief Accounting Officer | 1977 |
| Prof. Julie Frearson Ph.D. | Corp. Sr. VP & Chief Scientific Officer | NA |
| Mr. Mark Mintz | Corp. Sr. VP & Chief Information Officer | NA |
| Todd Spencer | Corp. VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...